$7.69
1.54% today
NYSE, Apr 03, 06:51 pm CET
ISIN
US05380C1027
Symbol
RCEL
Sector

AVITA Therapeutics Stock price

$7.81
-0.92 10.54% 1M
-3.20 29.06% 6M
-4.99 38.98% YTD
-7.41 48.69% 1Y
-1.01 11.45% 3Y
-21.19 73.07% 5Y
+2.06 35.83% 10Y
NYSE, Closing price Wed, Apr 02 2025
-0.36 4.41%
ISIN
US05380C1027
Symbol
RCEL
Sector

Key metrics

Market capitalization $194.02m
Enterprise Value $204.12m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.18
P/S ratio (TTM) P/S ratio 3.02
P/B ratio (TTM) P/B ratio 45.75
Revenue growth (TTM) Revenue growth 28.14%
Revenue (TTM) Revenue $64.25m
EBIT (operating result TTM) EBIT $-56.57m
Free Cash Flow (TTM) Free Cash Flow $-57.47m
Cash position $35.89m
EPS (TTM) EPS $-2.39
P/E forward negative
P/S forward 1.89
EV/Sales forward 1.99
Short interest 8.98%
Show more

Is AVITA Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

AVITA Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a AVITA Therapeutics forecast:

6x Buy
67%
3x Hold
33%

Analyst Opinions

9 Analysts have issued a AVITA Therapeutics forecast:

Buy
67%
Hold
33%

Financial data from AVITA Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
64 64
28% 28%
100%
- Direct Costs 9.09 9.09
17% 17%
14%
55 55
30% 30%
86%
- Selling and Administrative Expenses 90 90
37% 37%
141%
- Research and Development Expense 20 20
2% 2%
32%
-55 -55
54% 54%
-86%
- Depreciation and Amortization 1.09 1.09
28% 28%
2%
EBIT (Operating Income) EBIT -57 -57
54% 54%
-88%
Net Profit -62 -62
75% 75%
-96%

In millions USD.

Don't miss a Thing! We will send you all news about AVITA Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AVITA Therapeutics Stock News

Neutral
GlobeNewsWire
17 days ago
AVITA Medical announces new manufacturing agreement and amended distribution agreement with Stedical Scientific to further commercialization of PermeaDerm.
Neutral
GlobeNewsWire
about one month ago
AVITA Medical announced that Jim Corbett, CEO, will present at TD Cowen's 45th Annual Health Care Conference on March 4, 2025, at 11:50 a.m. Eastern Time.
Positive
Seeking Alpha
about one month ago
After Sales Rebound In January, AVITA Is Set Up For A Monster Year
More AVITA Therapeutics News

Company Profile

AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. Its product, RECELL system, is a device that enables healthcare professionals to produce a suspension of spray-on skin cells using a small sample of the patient's own skin for the treatment of acute thermal burns. The company was founded in December 1992 and is headquartered in Valencia, CA.

Head office United States
CEO James Corbett
Employees 260
Founded 1992
Website www.avitamedical.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today